In its second year, NLP has been ranked in the IAM Patent 1000 2026, in the “Firms: litigation and transactions” category, and promoted to the silver tier.
The Patent 1000 focuses exclusively on patent practice and has firmly established itself as the definitive 'go-to' resource for those seeking world-class legal patent expertise.
In the IAM 1000 words: “NLP has made a striking entrance into the Portuguese IP market, gaining traction quickly since its launch in 2024. Founded by three women, the firm combines technical capability with a clear strategic approach, advising across a range of innovation-led sectors. It is “highly organised in managing documentation, responsive in addressing queries, and adept at ensuring patent applications fully capture the breadth and versatility of an invention, with a clear ability to explain complex legal issues in a way that resonates with both technical and commercial audiences.” The team shows particular strength in biotechnology-related patent work, with a focus on aligning IP protection with commercial priorities.
Joana Piriquito Santos brings strong scientific grounding to the practice and “quickly grasps complex technical concepts, translating them into clear and robust patent language, while guiding the drafting and filing process with strategic foresight to ensure key aspects of an invention are fully protected.” She is supported by Beatriz Lima, an experienced litigator handling complex patent disputes across sectors including pharmaceuticals and telecommunications, and an active contributor to IP publications. Sara Nazaré focuses on high-value patent and SPC disputes, and is “a highly experienced and proactive practitioner, combining strong legal knowledge with clear, commercially focused advice while keeping clients informed of key developments.”
The founding trio has already appeared before the UPC, representing Boehringer in proceedings against Zentiva concerning a second medical use patent. The case tested the requirements for preliminary injunctions in the pharmaceutical sector, with an initial refusal overturned on appeal, marking an early and notable development for the Lisbon Local Division.
ompleting the line-up, Cláudia Freixinho Serrano adds further strength to the practice, drawing on over two decades of litigation experience, particularly in pharmaceutical and biotechnology patents, including the defence of originator products. Looking ahead, the firm is expanding into areas such as AI, software and digital law, positioning itself well for continued growth as the team.”
